Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]

以上数据源自公司内部合同金额统计，各项目交付周期差异较 大，不能以此直接推算公司本年度营业收入、净利润等财务数据。合 同可能根据客户需求或项目实际情况发生一定变动，也可能因统计口 径差异、税收等各种因素导致财务核算存在一定差异。以上数据仅供 投资者及时了解公司膜分离工程业务日常经营概况，公司财务数据以 公司披露的定期报告为准。敬请广大投资者理性投资，注意投资风险。 关于膜分离工程业务日常经营性合同情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）2025 年 4 月至 2025 年 6 月新签订的膜分离工程业务合同金额为人民币 650.33 万元。具 体情况如下： | 序号 | 应用领域 | 合同金额（万元） | | --- | --- | --- | | 1 | 膜法浓缩分离——盐湖提锂 | 180.00 | | 2 | 膜法工业废水处理及资源化利用——磷酸铁 | 342.36 | | 3 | 其他 | 127.97 | | | 合计 | 650.33 | 证券代码：000920 证券简称：沃顿科技 公告编号 ...

Group 1: Business Overview - The company operates in three main business segments: core membrane business, membrane separation engineering, and plant fiber business [1] - The core membrane business includes the R&D, manufacturing, and sales of separation membrane products, with applications in over 130 countries [1] - The plant fiber business focuses on the development and sales of eco-friendly furniture and bedding products [1] Group 2: Revenue Contribution - In 2024, revenue from membrane products reached CNY 1.033 billion, accounting for 59.23% of total revenue [2] - Plant fiber products contributed CNY 449.7 million, representing 25.79% of total revenue [2] - Membrane separation engineering generated CNY 156 million, making up 8.95% of total revenue [2] Group 3: Product Performance - Industrial membranes constitute approximately 70% of the membrane business revenue [2] - The impact of U.S.-China tariff adjustments on membrane business exports is minimal, as direct exports to the U.S. represent a small portion of total revenue [2] Group 4: Contract Performance - From January to March 2025, the company signed new contracts for membrane separation engineering worth CNY 62.76 million [2]

Core Points - The profit distribution plan for the fiscal year 2024 has been approved by the shareholders' meeting held on April 23, 2025, with a cash dividend of 1.47 RMB per 10 shares, totaling approximately 69.48 million RMB [1][2] - The distribution will be based on the total share capital of 472,621,118 shares as of the end of 2024, and the plan will be adjusted if there are changes in the share capital before implementation [1][2] - The dividend will be distributed to all shareholders registered by June 18, 2025, with the payment date set for June 19, 2025 [2][3] Profit Distribution Details - The cash dividend of 1.47 RMB per 10 shares is inclusive of tax, with different tax treatments for various types of shareholders [1][2] - For overseas institutions and certain individual shareholders, the net dividend after tax will be 1.323 RMB per 10 shares [1][2] - The tax rates for dividends vary based on the holding period of the shares, with specific amounts outlined for different durations [2] Distribution Method - The cash dividends will be directly credited to the shareholders' accounts through their custodial securities companies on the payment date [2][3] - The company will bear all legal responsibilities for any insufficient cash dividends during the distribution process [2][4] Consultation Information - Shareholders can consult the board office for any inquiries regarding the dividend distribution [3][4]

沃顿科技股份有限公司 证券代码：000920 证券简称：沃顿科技 公告编号：2025-036 2024 年年度分红派息实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东会审议通过利润分配方案情况 （一）沃顿科技股份有限公司（以下简称"公司"）2024 年度利润 分配方案已经 2025 年 4 月 23 日召开的 2024 年度股东会审议通过， 利润分配方案为：以公司 2024 年末总股本 472,621,118 股为基数，向 全体股东每 10 股派 1.47 元（含税），不以公积金转增股本，预计分 红金额 69,475,304.35 元，利润分配预案实施前，公司股本若发生变 动，将按照分配总额不变的原则对分配比例进行调整。 （二）自分配方案披露至实施期间公司股本总额未发生变化。 （三）本次实施的分配方案与股东会审议通过的分配方案及其调 整原则一致。 （四）本次实施分配方案距离股东会审议通过的时间未超过两个 月。 二、本次实施的利润分配方案 公司 2024 年度利润分配方案为：以公司现有总股本 472,621,118 股为基数，向全体股东每 10 ...

Core Insights - The ultrafiltration membrane industry is experiencing significant growth driven by increasing water quality demands and environmental awareness, with the market size in China projected to reach 6.8 billion yuan in 2024, representing a year-on-year growth of 9.68% [1][12]. Industry Overview - Ultrafiltration membranes are polymer separation membranes with a pore size typically ranging from 0.001 to 0.1 microns, capable of retaining particles larger than 10 nanometers while allowing water and small solutes to pass through [1][4]. - The industry has evolved through three main stages: initial exploration in the 1970s-80s, industrial breakthroughs in the 1990s-early 2000s, and rapid growth from the early 21st century to present [4][5]. Market Dynamics - The demand for ultrafiltration membranes is increasing in municipal water supply, wastewater treatment, and seawater desalination, as well as in the food and beverage and biopharmaceutical sectors [1][12]. - The urban sewage treatment capacity in China reached 234 million cubic meters per day in 2023, a year-on-year increase of 4.80%, highlighting the growing need for effective wastewater treatment solutions [10]. Industry Chain - The ultrafiltration membrane industry supply chain includes upstream raw materials (organic and inorganic materials), midstream manufacturing, and downstream applications in various sectors such as wastewater treatment, municipal water purification, and food and beverage [8]. Key Players - Major companies in the ultrafiltration membrane sector include Hainan Lifespan, Le Pure Biotechnology, and Beijing Sino, which are leveraging technological advancements to enhance their market positions [14][16]. - Hainan Lifespan has established itself as a leader with a production capacity of 30 million square meters annually, accounting for nearly half of global production [14][16]. Development Trends - The industry is witnessing technological innovations, such as Le Pure's Extreme™ PVDF membrane, which achieves a 99.9999% microbial retention rate, and advancements in membrane materials that enhance performance and sustainability [20][21]. - Market demand is shifting towards industrial wastewater treatment, municipal water supply improvements, and home water purification systems, with increasing consumer preferences for selective filtration products [21][22]. - Chinese ultrafiltration membrane companies are expanding globally, with initiatives to establish overseas production bases and participate in international standard-setting, enhancing their competitive edge [23].

Group 1: Business Overview - The industrial membrane currently accounts for approximately 70% of the company's membrane business revenue [1] - The company's membrane products are exported to over 130 countries and regions, projected to account for about 30% of total revenue in 2024 [2] Group 2: Product Applications - Household reverse osmosis membrane products are widely used in home health water applications, focusing on high-quality needs for sensitive users such as infants and the elderly [1] - The company is actively collaborating with application enterprises to accelerate the domestic substitution process of ultra-pure water key materials [2] Group 3: Financial Performance - In the first quarter, the company reported an operating income of 363 million yuan, an increase of 8.43% year-on-year [2] - The net profit attributable to the parent company was 44.45 million yuan, reflecting a year-on-year growth of 30.35% [2] - The average gross margin in the first quarter increased by 1.66% compared to previous periods, driven by the growth in membrane material sales [2] Group 4: Impact of Tariffs - The revenue from products directly exported to the United States is minimal, thus changes in China-U.S. tariff policies have a limited impact on the company's operations [1]

证券代码：000920 证券简称：沃顿科技 公告编号：2025-035 沃顿科技股份有限公司 关于参加 2025 年投资者集体接待日暨 2024 年度业绩说明会 并征集问题的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 沃顿科技股份有限公司（以下简称"公司"）已分别披露《2024 年年度报告》和《2025 年一季度报告》，为便于广大投资者更深入 全面地了解公司情况，公司将参加由贵州证监局指导、贵州证券业协 会与深圳市全景网络有限公司联合举办的 2025 年贵州辖区上市公司 投资者集体接待日暨 2024 年度业绩说明会并征集相关问题。本次活 动具体安排如下： 欢迎投资者积极参与问题征集，同时公司诚挚邀请广大投资者在 业绩说明会召开时间与公司出席的董事、高管进行交流。 特此公告。 一、业绩说明会的安排 召开时间：2025 年 5 月 12 日（星期一）15:40-17:40。 召开方式：网络远程方式。 出席人员：公司董事长蔡志奇先生，独立董事王立明先生，董事 会秘书赵峰先生，副总经理、财务总监兼总法律顾问郑巍先生。 参与方式：投资者可登录 http://r ...

Group 1: Financial Performance - The company's gross profit margin improved due to ongoing production line upgrades and enhanced production efficiency [1] - Supply chain management optimization and domestic material procurement significantly contributed to cost reduction and efficiency gains [1] Group 2: Capacity and Market Demand - Current production capacity can be further enhanced based on equipment upgrades, with infrastructure supporting additional capacity expansion [1] - The company can dynamically adapt its production scale to meet market demand increases, ensuring it does not become a bottleneck for growth [1] Group 3: Competitive Advantages - The company has achieved international advanced levels in product technology, tailored solutions to local application scenarios, and maintains a comprehensive service network [2] - Strong understanding of domestic industry policies and market characteristics allows for precise market trend identification and rapid product iteration [2] Group 4: Subsidiary Performance - The subsidiary, Daziran, leverages unique material properties to create differentiated competitive advantages and has built a stable customer base [3] - Daziran's introduction of a full-home customization brand enhances customer value and brand influence, aiming for stable revenue in 2024 despite challenging operating conditions [3]

Financial Performance - The company reported a basic earnings per share of 0.0940 yuan for Q1 2025, representing a 30.37% increase compared to 0.0721 yuan in Q1 2024 [1] - Net profit for Q1 2025 was 0.44 billion yuan, up 29.41% from 0.34 billion yuan in Q1 2024 [1] - Operating revenue reached 3.63 billion yuan in Q1 2025, an increase of 8.36% from 3.35 billion yuan in Q1 2024 [1] - The return on equity (ROE) improved to 2.34% in Q1 2025, compared to 1.88% in Q1 2024, marking a 24.47% increase [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 21,810.07 million shares, accounting for 51.68% of the circulating shares, with a decrease of 615,100 shares from the previous period [1] - The largest shareholder, CRRC Industry Investment Co., Ltd., holds 18,935.22 million shares, representing 44.87% of the total share capital, with no change in holdings [2] - The second largest shareholder, CRRC Guiyang Vehicle Co., Ltd., holds 1,192.42 million shares, also unchanged [2] - Notably, Xu Jiangfeng exited the top ten shareholders, while Gu Anqi entered as a new shareholder with 142.84 million shares [2] Dividend Policy - The company has decided not to distribute dividends or allocate bonus shares in this period [3]